AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31230508 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with heart failure with preserved ejection fraction
Number of subjects: 654
Study 31230508 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse pressure in women
Number of subjects: 654
Study 31230508 — intervention group
Group type: EXPERIMENTAL
Intervention: Men with heart failure with preserved ejection fraction
Number of subjects: 654
Study 31230614 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG)
Number of subjects: 204
Study 31230614 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosulfane blue (ISB)
Number of subjects: 204
Study 31230614 — intervention group
Group type: COMPARATOR
Intervention: Standard sectioning
Number of subjects: 204
Study 31230614 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrastaging
Number of subjects: 204
Study 31230614 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall SLN identification
Number of subjects: 204
Study 31230614 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral mapping
Number of subjects: 204
Study 31230614 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative predictive value (NPV)
Number of subjects: 204
Study 31230767 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeon-dominated approach to design of 3D-printed patient-specific surgical plates
Number of subjects: 16
Study 31231065 — intervention group
Group type: EXPERIMENTAL
Intervention: Segesterone acetate and ethinylestradiol contraceptive vaginal system (0.15 mg segesterone acetate and 0.013 mg ethinylestradiol per day) used for 13 cycles (1 year)
Number of subjects: 2278
Study 31231122 — intervention group
Group type: EXPERIMENTAL
Intervention: RRx-001 4 mg IV on day 1 of each week of a 21-day cycle followed by platinum plus etoposide (80-100 mg IV) at progression
Number of subjects: 26
Study 31231122 — intervention group
Group type: EXPERIMENTAL
Intervention: RRx-001
Number of subjects: 26
Study 31231276 — intervention group
Group type: EXPERIMENTAL
Intervention: Ayahuasca
Number of subjects: 0
Study 31231276 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 31231311 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel Continuous Remote Care Intervention Including Nutritional Ketosis
Number of subjects: 0
Study 31231311 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 31231443 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptide receptor radionuclide therapy (PRRT)
Number of subjects: 2
Study 31231443 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 2
Study 31231656 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention
Number of subjects: 0
Study 31231656 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study 31231785 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib 37.5 mg daily for 12 weeks
Number of subjects: 19
Study 31231944 — intervention group
Group type: EXPERIMENTAL
Intervention: Heartech® left ventricular partitioning device (LVPD)
Number of subjects: 16
Study 31233323 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency management (CM) intervention, details on dosage and duration not available.
Number of subjects: 0
Study 31233347 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 0
Study 31233392 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic hypertension
Number of subjects: 100
Study 31233392 — intervention group
Group type: COMPARATOR
Intervention: No chronic hypertension
Number of subjects: 100
Study 31233744 — intervention group
Group type: EXPERIMENTAL
Intervention: New objective CT analysis tool combining densitometry with machine learning
Number of subjects: 297
Study 31233744 — intervention group
Group type: EXPERIMENTAL
Intervention: New objective CT analysis tool
Number of subjects: 297
Study 31234786 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of Dependence Scale (SDS)
Number of subjects: 246
Study 31234866 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA) assessed by ActiGraph GT3X+ accelerometer over 7 days, average time of MVPA was 34.88 min/day.
Number of subjects: 2370
Study 31234866 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA) in Costa Rica and Peru.
Number of subjects: 2370
Study 31235325 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 104
Study 31235405 — intervention group
Group type: EXPERIMENTAL
Intervention: Cal09 LAIV
Number of subjects: 253
Study 31235405 — intervention group
Group type: EXPERIMENTAL
Intervention: NY15 LAIV
Number of subjects: 253
Study 31235405 — intervention group
Group type: EXPERIMENTAL
Intervention: NY15 LAIV (seronegative children)
Number of subjects: 253
Study 31235405 — intervention group
Group type: COMPARATOR
Intervention: Persistent shedding to day 7
Number of subjects: 253
Study 31235441 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib (400 mg per day continuously) plus trastuzumab (6 mg/kg every 3 weeks)
Number of subjects: 13
Study 31235483 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard chemotherapy plus biweekly cetuximab as first-line therapy
Number of subjects: 181
Study 31235483 — intervention group
Group type: COMPARATOR
Intervention: Clinical score with clinical variables only
Number of subjects: 181
Study 31235483 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical score with clinical variables and BRAF mutational status
Number of subjects: 181
Study 31235630 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ceftriaxone (75 to 100 mg/kg of body weight/day)
Number of subjects: 153
Study 31235775 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (BVZ) added to chemotherapy plus trastuzumab (Trast)
Number of subjects: 0
Study 31235775 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy plus trastuzumab (Trast)
Number of subjects: 0
Study 31235963 — intervention group
Group type: EXPERIMENTAL
Intervention: T cell receptor gene therapy targeting WT1
Number of subjects: 0
Study 31236272 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV vaccinated group
Number of subjects: 409
Study 31236272 — intervention group
Group type: COMPARATOR
Intervention: HPV unvaccinated group
Number of subjects: 409
Study 31236272 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated women
Number of subjects: 409
Study 31236272 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall study population
Number of subjects: 409
Study 31236579 — intervention group
Group type: EXPERIMENTAL
Intervention: Toripalimab (3 mg/kg d1, Q2W) as monotherapy in cohort 1
Number of subjects: 76
Study 31236579 — intervention group
Group type: EXPERIMENTAL
Intervention: Toripalimab (360 mg d1, Q3W) with oxaliplatin (130 mg/m2 qd, d1) and capecitabine (1000 mg/m2 b.i.d., d1-d14, Q3W) in cohort 2
Number of subjects: 76
Study 31236601 — intervention group
Group type: EXPERIMENTAL
Intervention: darunavir/cobicistat-based regimen
Number of subjects: 761
Study 31236809 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast compression
Number of subjects: 31
Study 31236847 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant nivolumab therapy
Number of subjects: 12
Study 31236954 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-min massage protocol applied by parents
Number of subjects: 0
Study 31236954 — intervention group
Group type: COMPARATOR
Intervention: Usual medical and nursing care given by neonatal units
Number of subjects: 0
Study 31237173 — intervention group
Group type: EXPERIMENTAL
Intervention: Defect-free care (implementation of all 8 AIS processes of care)
Number of subjects: 9485
Study 31237206 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene therapy for Leber's hereditary optic neuropathy
Number of subjects: 3
Study 31237839 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored Motivational Interviewing (TMI) implementation intervention (workshop and trigger-based coaching)
Number of subjects: 150
Study 31237839 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of internal facilitator coaching with encouragement of communities of practice (CoPs)
Number of subjects: 150
Study 31237839 — intervention group
Group type: COMPARATOR
Intervention: Communities of practice (CoPs) alone
Number of subjects: 150
Study 31237841 — intervention group
Group type: EXPERIMENTAL
Intervention: Seva (mHealth intervention)
Number of subjects: 268
Study 31238830 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapy (EVT) with or without intravenous tPA (IVT)
Number of subjects: 50
Study 31238830 — intervention group
Group type: COMPARATOR
Intervention: Intravenous tPA (IVT) only
Number of subjects: 50
Study 31238830 — intervention group
Group type: EXPERIMENTAL
Intervention: Revascularization patients
Number of subjects: 50
Study 31238830 — intervention group
Group type: COMPARATOR
Intervention: Non-revascularization patients
Number of subjects: 50
Study 31238832 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple thrombectomy passes
Number of subjects: 80
Study 31238832 — intervention group
Group type: COMPARATOR
Intervention: Single thrombectomy pass
Number of subjects: 80
Study 31238992 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Disease Self-Management Program (CDSMP)
Number of subjects: 24
Study 31239281 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin
Number of subjects: 24131
Study 31239281 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 24131
Study 31239311 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin and capecitabine (XELOX) plus D2 gastrectomy
Number of subjects: 54
Study 31239315 — intervention group
Group type: EXPERIMENTAL
Intervention: Less-experienced emergency physicians (≤10 years)
Number of subjects: 319
Study 31239315 — intervention group
Group type: COMPARATOR
Intervention: Experienced emergency physicians (>10 years)
Number of subjects: 319
Study 31239326 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia
Number of subjects: 389
Study 31239326 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline Alberta Stroke Program Early CT score (ASPECTS)
Number of subjects: 389
Study 31239326 — intervention group
Group type: EXPERIMENTAL
Intervention: IV-tPA
Number of subjects: 389
Study 31239326 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged time to treatment
Number of subjects: 389
Study 31239657 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 31239736 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib
Number of subjects: 0
Study 31239736 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 0
Study 31239857 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser Auriculotherapy (LAT)
Number of subjects: 145
Study 31239857 — intervention group
Group type: EXPERIMENTAL
Intervention: Magneto-Auriculotherapy (MAT)
Number of subjects: 145
Study 31239857 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of LAT and MAT
Number of subjects: 145
Study 31240302 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolbetuximab (monoclonal antibody) administered intravenously every 2 weeks for five planned infusions; cohorts received doses of 1300 mg/m2, 2600 mg/m2, and 3600 mg/m2.
Number of subjects: 54
Study 31240499 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ)
Number of subjects: 0
Study 31240499 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) monotherapy or combination therapy
Number of subjects: 0
Study 31240688 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin plus piperacillin-tazobactam
Number of subjects: 723
Study 31240688 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin-tazobactam alone
Number of subjects: 723
Study 31240688 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin alone
Number of subjects: 723
Study 31241031 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental stimulation (specifically stimulation specificity)
Number of subjects: 104
Study 31241031 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental feedback
Number of subjects: 104
Study 31241490 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme immunoassay (EIA) and chemiluminescence assay (CLIA) for IgM and IgG against B. burgdorferi
Number of subjects: 535
Study 31241558 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 31241745 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterus donation for transplantation
Number of subjects: 9
Study 31242023 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol
Number of subjects: 0
Study 31242023 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 0
Study 31242023 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 0
Study 31242362 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity troponin I concentrations of less than 6 ng per liter and an absolute change of less than 4 ng per liter after 45 to 120 minutes (early serial sampling)
Number of subjects: 22651
Study 31242362 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-assessment tool based on high-sensitivity troponin I or T concentration at presentation and dynamic change during serial sampling
Number of subjects: 22651
Study 31242746 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel ultrasound imaging and charge density mapping system for ablation of nonpulmonary vein targets
Number of subjects: 127
Study 31242863 — intervention group
Group type: EXPERIMENTAL
Intervention: Capillary blood smears
Number of subjects: 223
Study 31242863 — intervention group
Group type: EXPERIMENTAL
Intervention: Venous blood smears
Number of subjects: 223
Study 31242863 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple polymorphic markers
Number of subjects: 223
Study 31242873 — intervention group
Group type: EXPERIMENTAL
Intervention: STARPAC design
Number of subjects: 0
Study 31242873 — intervention group
Group type: COMPARATOR
Intervention: TITE-CRM
Number of subjects: 0
Study 31242873 — intervention group
Group type: COMPARATOR
Intervention: 3+3 design
Number of subjects: 0
Study 31242877 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration of depression management into routine HIV care
Number of subjects: 0
Study 31242877 — intervention group
Group type: COMPARATOR
Intervention: Standard HIV care without integrated depression management
Number of subjects: 0
Study 31243036 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-infrared spectroscopy-derived regional cerebral oxygenation (rSO2) measurement for 72 hours
Number of subjects: 0
Study 31243801 — intervention group
Group type: EXPERIMENTAL
Intervention: In-home respite care program
Number of subjects: 99
Study 31243801 — intervention group
Group type: COMPARATOR
Intervention: Standard dementia care
Number of subjects: 99
Study 31244718 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural menstrual cycle
Number of subjects: 44
Study 31244718 — intervention group
Group type: EXPERIMENTAL
Intervention: Fertility treatment (supraphysiological estradiol levels)
Number of subjects: 44
Study 31244760 — intervention group
Group type: EXPERIMENTAL
Intervention: CX-8998, a selective modulator of the T-Type calcium channel
Number of subjects: 0
Study 31244760 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31244884 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthocyanin supplementation
Number of subjects: 27
Study 31245054 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous abatacept 125 mg weekly for 24 weeks
Number of subjects: 425
Study 31245054 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 425
Study 31245160 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative endoscopic submucosal injection of dual tracer (radioisotope and indocyanine green) with sentinel basins detected using gamma-probe
Number of subjects: 237
Study 31245160 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic injection of indocyanine green (ICG) with sentinel basins detected using a fluorescence imaging system
Number of subjects: 237
Study 31245160 — intervention group
Group type: COMPARATOR
Intervention: Standard laparoscopic gastrectomy with lymphadenectomy
Number of subjects: 237
Study 31245263 — intervention group
Group type: EXPERIMENTAL
Intervention: STRIDE intervention involving a nurse falls care manager who assesses risks, suggests interventions, and creates individualized care plans.
Number of subjects: 5451
Study 31245263 — intervention group
Group type: EXPERIMENTAL
Intervention: Administrative data used for adjudication of serious fall injuries.
Number of subjects: 5451
Study 31245263 — intervention group
Group type: EXPERIMENTAL
Intervention: Participant self-report of falls leading to medical attention identified during telephone interviews every 4 months.
Number of subjects: 5451
Study 31246115 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 31246132 — intervention group
Group type: EXPERIMENTAL
Intervention: non-invasive vagus nerve stimulation (nVNS)
Number of subjects: 225
Study 31246132 — intervention group
Group type: COMPARATOR
Intervention: sham
Number of subjects: 225
Study 31246132 — intervention group
Group type: EXPERIMENTAL
Intervention: nVNS
Number of subjects: 225
Study 31246360 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS)
Number of subjects: 229
Study 31246589 — intervention group
Group type: EXPERIMENTAL
Intervention: PCSK9 inhibitors (evolocumab)
Number of subjects: 0
Study 31246589 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclisiran (siRNA)
Number of subjects: 0
Study 31247117 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg adefovir-dipivoxil (OAT1)
Number of subjects: 0
Study 31247117 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 0
Study 31247117 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0
Study 31247117 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin
Number of subjects: 0
Study 31247117 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 0
Study 31249371 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory blood pressure monitoring for 24 hours
Number of subjects: 22
Study 31249402 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatinine-based estimated glomerular filtration rate (eGFR) analysis in subjects with native kidneys
Number of subjects: 31
Study 31249784 — intervention group
Group type: EXPERIMENTAL
Intervention: Sebelipase alfa
Number of subjects: 1
Study 31249919 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 0
Study 31249919 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 31249987 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient management strategies for isolated distal deep-vein thrombosis
Number of subjects: 0
Study 31249987 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient management strategies for proximal deep-vein thrombosis
Number of subjects: 0
Study 31249989 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 31250322 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam oral solution (dosage increased weekly: 0.8, 1.6, 3.2 mg/kg/day for patients ≥ 8 years; 1.0, 2.0, 4.0 mg/kg/day for patients < 8 years)
Number of subjects: 100
Study 31250322 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam oral solution
Number of subjects: 100
Study 31250408 — intervention group
Group type: EXPERIMENTAL
Intervention: POCS-guided electrohydraulic or laser lithotripsy
Number of subjects: 156
Study 31250427 — intervention group
Group type: EXPERIMENTAL
Intervention: MedSafer electronic decision support tool for deprescribing
Number of subjects: 1066
Study 31250427 — intervention group
Group type: COMPARATOR
Intervention: Usual care (medication reconciliation)
Number of subjects: 1066
Study 31250445 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatment (selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, or vortioxetine) for 8 weeks
Number of subjects: 58
Study 31250445 — intervention group
Group type: COMPARATOR
Intervention: Control group (41 healthy controls)
Number of subjects: 58
Study 31250829 — intervention group
Group type: EXPERIMENTAL
Intervention: Feminizing hormone therapy and adherence counseling; Peer health navigation
Number of subjects: 0
Study 31251090 — intervention group
Group type: EXPERIMENTAL
Intervention: mepolizumab single-use prefilled autoinjector
Number of subjects: 0
Study 31251440 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in sputum neutrophils
Number of subjects: 40
Study 31251440 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in sputum eosinophils
Number of subjects: 40
Study 31251543 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% A/BPO treatment
Number of subjects: 50
Study 31252347 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention to delay repeat pregnancy
Number of subjects: 331
Study 31252347 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 331
Study 31253124 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab-based infusional 5-fluorouracil regimen
Number of subjects: 120
Study 31253196 — intervention group
Group type: EXPERIMENTAL
Intervention: Major Depressive Disorder (MDD)
Number of subjects: 1112
Study 31253196 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttraumatic Stress Disorder (PTSD)
Number of subjects: 1112
Study 31253196 — intervention group
Group type: COMPARATOR
Intervention: Schizophrenia Spectrum Disorders (SSD)
Number of subjects: 1112
Study 31253196 — intervention group
Group type: COMPARATOR
Intervention: General Population
Number of subjects: 1112
Study 31253237 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive outreach
Number of subjects: 2654
Study 31253237 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 2654
Study 31253437 — intervention group
Group type: EXPERIMENTAL
Intervention: Unified Protocol (UP)
Number of subjects: 223
Study 31253437 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Disorder Protocol (SDP)
Number of subjects: 223
Study 31253437 — intervention group
Group type: COMPARATOR
Intervention: Waitlist
Number of subjects: 223
Study 31253540 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezacaftor/ivacaftor
Number of subjects: 70